Engel Law PLLC is investigating whether fair value to Spectrum shareholders will result from the proposed acquisition of each share of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) by Assertio Holdings, Inc. for both of: (i) 0.1783 shares of Assertio common stock, and (ii) one CVR per Spectrum share worth up to an additional $0.20 per share.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.